Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Interpace Diagnostics Group (PF4) Stock Price & Analysis

0 Followers

PF4 Stock Chart & Stats

€6.40€0.00(0.00%)
At close: 5:30 PM GMT+1
€5€6€7Sep 8Feb 20Aug 11
Day’s Range
EUR 6.40 - EUR 6.45
52-Week Range
EUR 3.65 - EUR 8.60
Previous Close
EUR 6.40
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 36.81M
Enterprise Value
EUR 43.46M
Total Cash (Recent Filing)
EUR 2.69M
Total Debt (Recent Filing)
EUR 974.00K
Price to Earnings (P/E)
0.2
Beta
-0.24
Next Earnings
Nov 11, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Profitability Turnaround

The shift from sizable earlier losses to sustained profitability through 2023–2025 indicates materially improved operating performance. If maintained, positive operating income can strengthen internal funding capacity, support investment in diagnostic offerings, and reduce reliance on external capital over the next several quarters.

Balance Sheet Strength

Positive equity combined with very low debt gives the company greater financial flexibility than in prior periods when equity was negative. Minimal leverage can reduce financing pressure, improve resilience during revenue softness, and preserve capacity to fund operations or strategic initiatives.

Positive Cash Generation

Positive operating and free cash flow provide evidence that the business is converting reported profitability into funding for ongoing operations. Free cash flow close to net income is generally supportive of earnings quality and can help the company finance needs without depending heavily on new borrowing.

Bears Say

Revenue Decline

Falling revenue weakens the underlying growth profile of the diagnostics business and may limit operating leverage, reinvestment capacity, and future earnings expansion. Continued contraction could offset recent profitability gains by reducing test volume or the revenue base supporting fixed operating costs.

Weakening Cash Conversion

Although cash generation remains positive, weaker TTM growth and operating cash flow below net income show that cash conversion has deteriorated. If this pattern persists, reported earnings may translate less effectively into resources for investment, debt avoidance, or other corporate priorities.

Earnings Predictability

An unusually high net margin alongside declining revenue makes the current earnings run-rate less predictable. If profitability depends partly on non-core items rather than recurring diagnostic activity, future results may be more volatile and the recent turnaround may prove less durable.

PF4 FAQ

What was Interpace Diagnostics Group’s price range in the past 12 months?
Interpace Diagnostics Group lowest stock price was €3.65 and its highest was €8.60 in the past 12 months.
What is Interpace Diagnostics Group’s market cap?
Interpace Diagnostics Group’s market cap is €36.81M.
When is Interpace Diagnostics Group’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Interpace Diagnostics Group’s earnings last quarter?
Interpace Diagnostics Group released its earnings results on Aug 10, 2026. The company reported €0.025 earnings per share for the quarter.
Is Interpace Diagnostics Group overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Interpace Diagnostics Group pay dividends?
Interpace Diagnostics Group does not currently pay dividends.
What is Interpace Diagnostics Group’s EPS estimate?
Interpace Diagnostics Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Interpace Diagnostics Group have?
Interpace Diagnostics Group has 5,901,962 shares outstanding.
What happened to Interpace Diagnostics Group’s price movement after its last earnings report?
Interpace Diagnostics Group reported an EPS of €0.025 in its last earnings report. Following the earnings report the stock price went up 2.963%.
Which hedge fund is a major shareholder of Interpace Diagnostics Group?
Currently, no hedge funds are holding shares in DE:PF4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology